Testosterone Sustained Release Microspheres for the Treatment of Fecal Incontinence

J Pharm Sci. 2022 Aug;111(8):2322-2329. doi: 10.1016/j.xphs.2022.03.008. Epub 2022 Mar 19.

Abstract

The objective of this study was to develop a testosterone sustained release formulation for the treatment of fecal incontinence. To suppress the initial burst release of testosterone, which can lead to systemic toxicity, we incorporated a washing step using an aminoalkyl methacrylate copolymer E solution or propylene glycol solution into a typical o/w emulsion method to prepare polylactic-co-glycolic acid microspheres. We used this method to develop a polylactic-co-glycolic acid microsphere formulation that shows sustained release of testosterone for up to one month. Not only did this formulation show a sustained release profile after administration into the intersphincteric groove in minipigs, it also increased both the anal pressure and mass of the external anal sphincter, while keeping systemic testosterone exposure low. Thus, this formulation successfully affected both the internal and external anal sphincters with a sufficient safety profile, deeming it a promising candidate treatment strategy for fecal incontinence.

Keywords: Controlled release; Long-acting; Microsphere(s); Muscle(s); Polyglycolic acid (PLGA); Polylactic acid (PLA).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Delayed-Action Preparations
  • Fecal Incontinence* / drug therapy
  • Lactic Acid
  • Microspheres
  • Particle Size
  • Polyglycolic Acid*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Swine
  • Swine, Miniature
  • Testosterone

Substances

  • Delayed-Action Preparations
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Testosterone